How do you determine treatment failure of erythropoiesis-stimulating agents (ESAs) in your patients with myelodysplastic syndrome (MDS)? What criteria do you use?
a) Hemoglobin levels below 7 g/dL
b) Platelet count above 500,000/mm³
c) Increase in red blood cell count
d) Normal reticulocyte count
